Neuphoria Therapeutics Inc
Company Profile
Business description
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
Contact
100 Summit Drive
BurlingtonMA01803
USAT: +1 781 439-5551
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
8
Stocks News & Analysis
stocks
Investors overlooking ASX share’s potential
stocks
Cerebras sees blockbuster demand, setting stage for US AI IPO frenzy
stocks
What did Morningstar subscribers buy and sell in April?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,880.40 | 36.90 | -0.41% |
| CAC 40 | 8,082.27 | 0.00 | 0.00% |
| DAX 40 | 24,456.26 | 319.45 | 1.32% |
| Dow JONES (US) | 50,063.46 | 370.26 | 0.75% |
| FTSE 100 | 10,372.93 | 47.58 | 0.46% |
| HKSE | 26,155.33 | 233.71 | -0.89% |
| NASDAQ | 26,635.22 | 232.88 | 0.88% |
| Nikkei 225 | 62,141.93 | 512.12 | -0.82% |
| NZX 50 Index | 12,951.78 | 73.29 | -0.56% |
| S&P 500 | 7,501.24 | 56.99 | 0.77% |
| S&P/ASX 200 | 8,637.50 | 36.00 | -0.42% |
| SSE Composite Index | 4,144.33 | 33.58 | -0.80% |